What are the AACE recommendations for drug selection in the treatment of osteoporosis?

Updated: Aug 27, 2020
  • Author: Monique Bethel, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Guidelines from the American Association of Clinical Endocrinologists include the following recommendations for choosing drugs to treat osteoporosis [12] :

  • First-line agents for most high fracture risk patients: alendronate, risedronate, zoledronate, denosumab
  • First-line agents for high fracture risk patients unbale to use oral therapy: baloparatide, denosumab, romosozumab, teriparatide, and zoledronate
  • First-line agents for spine-specific indications in select patients: ibandronate and raloxifene
  • Sequential agents: anabolic agents (e.g., abaloparatide, romosozumab, teriparatide) should be followed with a bisphosphonate or denosumab

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!